ABCELLERA BIOLOGICS INC (ABCL) Stock Overview
USA - NASDAQ:ABCL - CA00288U1066 - Common Stock
ABCL Key Statistics, Chart & Performance
The current stock price of ABCL is 4.51 USD. In the past month the price increased by 4.88%. In the past year, price increased by 74.13%.
ABCL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 21.91 | 181.09B | ||
| DHR | DANAHER CORP | 25.67 | 138.41B | ||
| A | AGILENT TECHNOLOGIES INC | 23.18 | 35.81B | ||
| IQV | IQVIA HOLDINGS INC | 16.32 | 31.83B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 30.94 | 26.07B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 36.62 | 18.33B | ||
| WAT | WATERS CORP | 24.6 | 17.91B | ||
| ILMN | ILLUMINA INC | 24.7 | 15.79B | ||
| TEM | TEMPUS AI INC | N/A | 15.33B | ||
| MEDP | MEDPACE HOLDINGS INC | 37.07 | 14.01B | ||
| ICLR | ICON PLC | 13.15 | 13.53B | ||
| RVTY | REVVITY INC | 17.73 | 10.07B |
Related stock screener links
About ABCL
Company Profile
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 596 full-time employees. The company went IPO on 2020-12-11. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. The company is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
Company Info
ABCELLERA BIOLOGICS INC
150 W 4Th Avenue
Vancouver BRITISH COLUMBIA CA
Employees: 596
Phone: 16045599005
ABCELLERA BIOLOGICS INC / ABCL FAQ
What is the stock price of ABCELLERA BIOLOGICS INC today?
The current stock price of ABCL is 4.51 USD. The price decreased by -4.45% in the last trading session.
What is the ticker symbol for ABCELLERA BIOLOGICS INC stock?
The exchange symbol of ABCELLERA BIOLOGICS INC is ABCL and it is listed on the Nasdaq exchange.
On which exchange is ABCL stock listed?
ABCL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ABCELLERA BIOLOGICS INC stock?
14 analysts have analysed ABCL and the average price target is 9.47 USD. This implies a price increase of 110.01% is expected in the next year compared to the current price of 4.51. Check the ABCELLERA BIOLOGICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ABCELLERA BIOLOGICS INC worth?
ABCELLERA BIOLOGICS INC (ABCL) has a market capitalization of 1.35B USD. This makes ABCL a Small Cap stock.
How many employees does ABCELLERA BIOLOGICS INC have?
ABCELLERA BIOLOGICS INC (ABCL) currently has 596 employees.
What are the support and resistance levels for ABCELLERA BIOLOGICS INC (ABCL) stock?
ABCELLERA BIOLOGICS INC (ABCL) has a support level at 4.34 and a resistance level at 4.74. Check the full technical report for a detailed analysis of ABCL support and resistance levels.
Is ABCELLERA BIOLOGICS INC (ABCL) expected to grow?
The Revenue of ABCELLERA BIOLOGICS INC (ABCL) is expected to grow by 4.72% in the next year. Check the estimates tab for more information on the ABCL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ABCELLERA BIOLOGICS INC (ABCL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ABCL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ABCL, evaluating the profitability, health, valuation and growth aspects
- ABCELLERA BIOLOGICS INC (ABCL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ABCELLERA BIOLOGICS INC (ABCL) Sales and EPS estimates to see what analysts future expectations are.
- ABCELLERA BIOLOGICS INC (ABCL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ABCELLERA BIOLOGICS INC (ABCL) Insider and Institutional Ownership to learn about the owners and their transactions.
- ABCELLERA BIOLOGICS INC (ABCL) Stock Chart to make your own analysis
- ABCELLERA BIOLOGICS INC (ABCL) Latest news and press-releases to stay up to date.
Does ABCELLERA BIOLOGICS INC (ABCL) stock pay dividends?
ABCL does not pay a dividend.
When does ABCELLERA BIOLOGICS INC (ABCL) report earnings?
ABCELLERA BIOLOGICS INC (ABCL) will report earnings on 2025-11-03, after the market close.
What is the Price/Earnings (PE) ratio of ABCELLERA BIOLOGICS INC (ABCL)?
ABCELLERA BIOLOGICS INC (ABCL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.55).
What is the Short Interest ratio of ABCELLERA BIOLOGICS INC (ABCL) stock?
The outstanding short interest for ABCELLERA BIOLOGICS INC (ABCL) is 19.05% of its float. Check the ownership tab for more information on the ABCL short interest.
ABCL Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ABCL. When comparing the yearly performance of all stocks, ABCL is one of the better performing stocks in the market, outperforming 91.28% of all stocks.
ABCL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ABCL. No worries on liquidiy or solvency for ABCL as it has an excellent financial health rating, but there are worries on the profitability.
ABCL Financial Highlights
Over the last trailing twelve months ABCL reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS decreased by -1.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.82% | ||
| ROE | -16.45% | ||
| Debt/Equity | 0 |
ABCL Forecast & Estimates
14 analysts have analysed ABCL and the average price target is 9.47 USD. This implies a price increase of 110.01% is expected in the next year compared to the current price of 4.51.
For the next year, analysts expect an EPS growth of -13.13% and a revenue growth 4.72% for ABCL